UroGen Pharma
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell UroGen Pharma and other ETFs, options, and stocks.About URGN
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology.
URGN Key Statistics
Stock Snapshot
The current UroGen Pharma(URGN) stock price is $22.87, with a market capitalization of 1.08B. The stock trades at a price-to-earnings (P/E) ratio of -7.01.
On 2025-11-07, UroGen Pharma(URGN) stock moved within a range of $21.75 to $23.89. With shares now at $22.87, the stock is trading +5.1% above its intraday low and -4.3% below the session's peak.
Trading activity shows a volume of 2.07M, compared to an average daily volume of 1.45M.
The stock's 52-week range extends from a low of $3.42 to a high of $23.90.
The stock's 52-week range extends from a low of $3.42 to a high of $23.90.
URGN News
Urogen Pharma ((URGN)) has held its Q3 earnings call. Read on for the main highlights of the call. Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analys...
Urogen Pharma ( (URGN) ) has released its Q3 earnings. Here is a breakdown of the information Urogen Pharma presented to its investors. Meet Your ETF AI Analys...
Earnings Call Insights UroGen outlines $1B ZUSDURI peak revenue ambition as adoption set to accelerate with permanent J-code in 2026 Nov. 06, 2025 10:26 PM ET U...
Analyst ratings
88%
of 8 ratingsMore URGN News
In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Urogen Pharma, with a price target of $35.00. Meet Your ETF AI Analyst Discov...
Reports Q3 revenue $27.482M, consensus $32.47M. “Our launch of ZUSDURI, the first and only FDA-approved medicine for adults with recurrent low-grade intermediat...